{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T08:54:18+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective NIS to generate real-world-data on Effectiveness and Safety of first-line therapy with Chemotherapy combined with Durvalumab followed by maintenance therapy with Durvakumab or Durvalumab + Olaparib in endometrial Cancer","eudractNumber":null,"id":11842,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"}],"mutations":[],"nctNumber":"NCT06890273","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-24T10:23:30+01:00","shortTitle":"Duolife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<u>E</u>ffekt einer <u>c</u>oordinierten <u>H</u>ilfestellung f&#252;r <u>T</u>umorpatienten durch intensivierte Supportivangebote: <u>e</u>ine <u>r</u>andomisierte kontrollierte Studie","eudractNumber":null,"id":2820,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2016-12-16T15:02:20+01:00","shortTitle":"ECHTER-001","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ergebnisqualit&#228;t bei Darmkrebs: Identifikation von Unterschieden und Ma&#223;nahmen zur fl&#228;chendeckenden Qualit&#228;tsentwicklung","eudractNumber":null,"id":10690,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-01-01T08:53:12+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ergebnisqualit&#228;t bei Darmkrebs: Identifikation von Unterschieden und Ma&#223;nahmen zur fl&#228;chendeckenden Qualit&#228;tsentwicklung","eudractNumber":null,"id":5299,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-01T12:33:08+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ergebnisqualit&#228;t bei Darmkrebs: Identifikation von Unterschieden und Ma&#223;nahmen zur fl&#228;chendeckenden Qualit&#228;tsentwicklung","eudractNumber":null,"id":11661,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-01T14:29:16+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, f&#252;r die Behandlung des Melanoms","eudractNumber":"2024-512659-19-00","id":11739,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT06697301","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-11-26T11:42:59+01:00","shortTitle":"EIK1001-006","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/ bortezomib/ dexamethasone (I-VRD) followd by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followd standard of care intensification followed by maintenance therapy with lenalidomide and isatuximab<div><br /></div><div>Short title: Expression-linked and R-Iss-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)</div>","eudractNumber":"2020-005102-26","id":9532,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05665140","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-07-01T12:46:18+02:00","shortTitle":"ELIAS","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div><br /></div>Mantelzell-Register, Einschluss aller Linien","eudractNumber":null,"id":7531,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-11-01T12:47:28+01:00","shortTitle":"EMCL Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued</div><div>Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients</div>","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}